Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder.

Pagerols M, Richarte V, Sánchez-Mora C, Garcia-Martínez I, Corrales M, Corominas M, Cormand B, Casas M, Ribasés M, Ramos-Quiroga JA.

Pharmacogenomics J. 2017 Jan;17(1):98-104. doi: 10.1038/tpj.2015.89. Epub 2016 Jan 26.

PMID:
26810137
2.

Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients.

Angyal N, Horvath EZ, Tarnok Z, Richman MJ, Bognar E, Lakatos K, Sasvari-Szekely M, Nemoda Z.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jun 8;84(Pt A):122-128. doi: 10.1016/j.pnpbp.2018.01.013. Epub 2018 Feb 20.

PMID:
29374517
3.

Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder.

Gruber R, Joober R, Grizenko N, Leventhal BL, Cook EH Jr, Stein MA.

J Child Adolesc Psychopharmacol. 2009 Jun;19(3):233-9. doi: 10.1089/cap.2008.0133.

4.

A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder.

McGough JJ, McCracken JT, Loo SK, Manganiello M, Leung MC, Tietjens JR, Trinh T, Baweja S, Suddath R, Smalley SL, Hellemann G, Sugar CA.

J Am Acad Child Adolesc Psychiatry. 2009 Dec;48(12):1155-64. doi: 10.1097/CHI.0b013e3181bc72e3.

5.

Catechol-O-methyltransferase Val158-Met polymorphism and a response of hyperactive-impulsive symptoms to methylphenidate: A replication study from South Korea.

Park S, Kim JW, Kim BN, Shin MS, Yoo HJ, Cho SC.

J Psychopharmacol. 2014 Jul;28(7):671-6. doi: 10.1177/0269881114527654. Epub 2014 Apr 24.

PMID:
24763183
6.

ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD.

Kim SW, Lee JH, Lee SH, Hong HJ, Lee MG, Yook KH.

J Clin Psychopharmacol. 2013 Aug;33(4):491-8. doi: 10.1097/JCP.0b013e3182905a8d.

PMID:
23771192
7.

Pharmacogenetics of response to methylphenidate in adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD): a systematic review.

Contini V, Rovaris DL, Victor MM, Grevet EH, Rohde LA, Bau CH.

Eur Neuropsychopharmacol. 2013 Jun;23(6):555-60. doi: 10.1016/j.euroneuro.2012.05.006. Epub 2012 Jun 17. Review.

PMID:
22709890
8.

Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths.

Leddy JJ, Waxmonsky JG, Salis RJ, Paluch RA, Gnagy EM, Mahaney P, Erbe R, Pelham WE, Epstein LH.

J Child Adolesc Psychopharmacol. 2009 Apr;19(2):127-36. doi: 10.1089/cap.2008.046.

PMID:
19364291
9.

Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder.

Kim BN, Kim JW, Cummins TD, Bellgrove MA, Hawi Z, Hong SB, Yang YH, Kim HJ, Shin MS, Cho SC, Kim JH, Son JW, Shin YM, Chung US, Han DH.

J Clin Psychopharmacol. 2013 Jun;33(3):356-62. doi: 10.1097/JCP.0b013e31828f9fc3.

PMID:
23609393
10.

A candidate gene investigation of methylphenidate response in adult attention-deficit/hyperactivity disorder patients: results from a naturalistic study.

Hegvik TA, Jacobsen KK, Fredriksen M, Zayats T, Haavik J.

J Neural Transm (Vienna). 2016 Aug;123(8):859-65. doi: 10.1007/s00702-016-1540-7. Epub 2016 Apr 18.

11.

Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children.

Kereszturi E, Tarnok Z, Bognar E, Lakatos K, Farkas L, Gadoros J, Sasvari-Szekely M, Nemoda Z.

Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1431-5. doi: 10.1002/ajmg.b.30704.

PMID:
18214865
12.

Dopaminergic and noradrenergic gene polymorphisms and response to methylphenidate in korean children with attention-deficit/hyperactivity disorder: is there an interaction?

Hong SB, Kim JW, Cho SC, Shin MS, Kim BN, Yoo HJ.

J Child Adolesc Psychopharmacol. 2012 Oct;22(5):343-52. doi: 10.1089/cap.2011.0076.

PMID:
23083021
13.

Some ADHD polymorphisms (in genes DAT1, DRD2, DRD3, DBH, 5-HTT) in case-control study of 100 subjects 6-10 age.

Kopecková M, Paclt I, Petrásek J, Pacltová D, Malíková M, Zagatová V.

Neuro Endocrinol Lett. 2008 Apr;29(2):246-51.

PMID:
18404133
14.

Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders.

McCracken JT, Badashova KK, Posey DJ, Aman MG, Scahill L, Tierney E, Arnold LE, Vitiello B, Whelan F, Chuang SZ, Davies M, Shah B, McDougle CJ, Nurmi EL.

Pharmacogenomics J. 2014 Jun;14(3):295-302. doi: 10.1038/tpj.2013.23. Epub 2013 Jul 16.

15.

No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder.

Zeni CP, Guimarães AP, Polanczyk GV, Genro JP, Roman T, Hutz MH, Rohde LA.

Am J Med Genet B Neuropsychiatr Genet. 2007 Apr 5;144B(3):391-4.

PMID:
17171656
16.

Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia.

Golubchik P, Sever J, Weizman A.

Int Clin Psychopharmacol. 2014 Jul;29(4):212-5. doi: 10.1097/YIC.0000000000000029.

17.
18.

Pharmacogenetics of methylphenidate response in attention deficit/hyperactivity disorder: association with the dopamine transporter gene (SLC6A3).

Purper-Ouakil D, Wohl M, Orejarena S, Cortese S, Boni C, Asch M, Mouren MC, Gorwood P.

Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1425-30. doi: 10.1002/ajmg.b.30809.

PMID:
18563707
19.

Pharmacogenetics of methylphenidate in childhood attention-deficit/hyperactivity disorder: long-term effects.

Gomez-Sanchez CI, Carballo JJ, Riveiro-Alvarez R, Soto-Insuga V, Rodrigo M, Mahillo-Fernandez I, Abad-Santos F, Dal-Ré R, Ayuso C.

Sci Rep. 2017 Sep 4;7(1):10391. doi: 10.1038/s41598-017-10912-y.

20.

Supplemental Content

Support Center